Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says
Executive Summary
Hormone therapy drug sponsors seeking approval for osteoporosis do not need to submit to FDA any extraordinary safety data in light of the WHI findings, Metabolic & Endocrine Division Director David Orloff, MD, said Oct. 7
You may also be interested in...
Prempro Osteoporosis Use In Older Women May Be Limited To Second-Line
Wyeth is considering revising Prempro's indication to more clearly define the hormone therapy as second-line osteoporosis prevention for older women
Prempro Osteoporosis Use In Older Women May Be Limited To Second-Line
Wyeth is considering revising Prempro's indication to more clearly define the hormone therapy as second-line osteoporosis prevention for older women
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative